Next-Generation Sequencing

NGS solutions for genomic surveillance of SARS-CoV-2

In the race against the virus, hours and minutes matter

The latest twist in the COVID-19 pandemic is the alarming emergence of new SARS-CoV-2 variants of concern, such as lineages Alpha, Beta, Gamma and Delta, Mu and Omicron. The potential for new variants to evade the immune response, lowering the efficacy of vaccines remains a threat. Labs are therefore under pressure to sequence samples as quickly as possible to identify new and catalog existing SARS-CoV-2 variants circulating in the population. To help you accelerate your SARS-CoV-2 genomic surveillance efforts, we’ve developed two tailored solutions for viral amplification and NGS library preparation.

Get the right genomic surveillance solution for your needs

The faster you can sequence samples, the quicker you can develop a comprehensive picture of circulating variants, allowing you to stay one step ahead. Explore how our genomic surveillance solutions can help.


Accelerate SARS-CoV-2 genomic surveillance with a 50% faster, high-throughput NGS solution. The high-performance QIAseq DIRECT SARS-CoV-2 Kit ensures superior coverage with a 4-hour, automatable workflow and a 50% reduction in plasticware use.

Why choose the QIAseq DIRECT SARS-CoV-2 Kit?

Use our ultrafast, high-throughput, single-box NGS solution if you want to maximize efficiency, ramp up your sequencing capability and ensure superior coverage to accelerate variant detection.

QIAseq SARS-CoV-2 Primer Panel

Expedite SARS-CoV-2 variant detection and real-time genomic surveillance with our scalable, single-day workflow, which is faster and has lower-input requirements than hybrid capture solutions. Based on optimized publicly available ARTIC V3 designs, the QIAseq SARS-CoV-2 Primer Panel provides targeted enrichment of the complete viral genome, allowing you to:

  • Achieve high coverage, even at low copy number due to reduced primer dropouts and primer-dimer effects
  • Multiplex up to 384 samples in a single run on high-throughput Illumina platforms
  • Track and visualize phylogenetic divergence with integrated bioinformatics analysis pipelines
A winning combination for improved scalability

Combine the QIAseq SARS-CoV-2 Primer Panel with the QIAseq FX DNA Library UDI Kit to multiplex up to 384 samples in a single run.

Get started with a trial kit
Genomics, QIAseq NGS Solutions, Dr. Mette Christiansen, Aarhus University hospital, COVID-1
Sequencing COVID-19 mutations after jumping species

By November 2020, more than 200 people in Denmark were believed to have caught COVID-19 from mink. Meanwhile, the virus had been mutating within the animals, resulting in a handful of variants. Dr. Mette Christiansen, Head of the Diagnostic NGS Core Facility, Molecular Medicine (MOMA) at Aarhus University Hospital, discusses the how sequencing all positive cases helped achieve a clear picture of circulating variants. Explore how QIAGEN NGS technologies facilitated this effort.

Ramp up your lab's SARS-CoV-2 sequencing capability
Discuss your project needs with our specialists.


We call to increase the sequencing of the virus, to supplement ongoing surveillance, monitoring and test efforts
Director-General, World Health Organization

Check out our webinars

Accelerating SARS-CoV-2 genomic surveillance with a new high-throughput NGS solution

Speakers: Brian Dugan, M.S., Associate Director, Global Product Management, Genomics, QIAGEN and Fernando Spilki, Ph.D., Feevale University, Novo Hamburgo, Brazil

Corona virus
World map on a tablet screen
Enabling high-throughput genomic surveillance of emerging SARS-CoV-2 strains B.1.1.7 and B.1.351
Speakers: Brian Dugan, M.S., Associate Director, Global Product Management, Genomics, QIAGEN and Shawn Prince, B.S., Senior Field Application Scientist, Bioinformatics, QIAGEN
Expand insights into SARS-CoV-2 metatranscriptomics
Explore how our innovative NGS solutions can enhance RNA-seq sensitivity in SARS-CoV-2 metatranscriptomics research.

Dive deeper

Contact us

All photos taken prior to COVID-19
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.